echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > With a tube of blood for accurate tumor detection, what's so great about Guardant Health, which can be used against Grail?

    With a tube of blood for accurate tumor detection, what's so great about Guardant Health, which can be used against Grail?

    • Last Update: 2020-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Liquid biopsy is a non-invasive and simple detection method, which can detect cancer by detecting the number of circulating tumor cells, circulating tumor DNA and tumor extracellular progenitor in the blood, and has great application prospects in the areas of early diagnosis of tumor, prediction of therapeutic efficacy and prognosis, detection of recurrence, tumor heterogeneity and evolution.
    Since it was named one of the top ten breakthrough technologies in 2015 by MIT Technology Review, the broad application prospects of liquid biopsy technology in cancer diagnosis and treatment have been paid more and more attention by the enterprise capital market, and the heat has been increasing, which has become a breakthrough in the accurate diagnosis and treatment of tumors.
    recent years, the total number of liquid biopsy enterprises in China has continued to grow, and the 2019 China Liquid Biopsy Industry In-depth Study Report shows that by the end of 2018, more than 157 enterprises in China had laid out liquid biopsy fields.
    has been growing at a high rate since 2010, peaking in 2015 with 28 companies registered in 2015.
    of these, most of them focus on the tumor detection track.
    And abroad, the tumor liquid biopsy industry has emerged Guardant Health, Medicine Foundation, Grail, Myriad and other enterprises, and a number of tumor liquid biopsy products approved to meet the needs of different patients, and gradually the tumor gene testing as an accompanying diagnosis, deep binding targeted drug use, and truly achieve treatment accuracy.
    at a time of increasingly fierce competition in China, arterial network to industry leader Guardant Health as an example, from the enterprise's product layout, business model, financing situation and other perspectives to comb, hoping to provide reference for the development of domestic enterprises.
    $550 million helmy Eltoukhy is the founder and CEO of Goodant Health and holds a Ph.D. in Electrical Engineering from Stanford University.
    2006, Helmy Eltoukhy worked on a new generation of low-cost, high-read long gene sequencing platforms at Stanford University's Genomics Technology Center, and based on that research, co-founded Avantome in 2007.
    Avantome was acquired by Illumina in August 2008.
    founded Guardant Health in California in 2012 after a long-term business.
    , a cancer liquid biopsy star, has always believed that the key to fighting tumors is to have accurate molecular information at all stages of the disease.
    , Guardant Health is passing blood genetic testing to provide guidance on medication, recurrence monitoring, and early screening products for cancer patients.
    note that the company's focus is on detecting tumors at an early curable stage, known as early sieve.
    , Guardant Health completed a $1,000 round of A-round financing in February 2014, followed by a $30 million investment in Khosla Ventures, Sequoia Capital and others in April, according to Churchbase. Round B financing; $50 million round C financing completed in 2015; $100 million round D financing completed in 2016; and $360 million round E financing completed by SoftBank In 2017.
    $550 million in cumulative financing, which, while no more dazzling than another company, Grail, is enough to make it a star in the field of tumor liquid biopsies.
    2018, Guardant Health is listed on NASDAQ.
    market capitalisation of $11.06 billion as of September 30, 2020.
    product line covers the full cycle of tumor diagnosis, early screening is a key product based on NGS deep sequencing technology platform, Guardant Health's research and development layout basically covers the full cycle stage of tumor detection, the company's four products: Guardant360 and GuardantOMNI for monitoring the genetic mutations of patients with advanced cancer, LUNAR-1 for recurrence monitoring, LUNAR-2 for cancer early screening.
    . Guardant360: For patients with advanced solid tumors, theguardant360, the first commercialized product of Guardant Health, was launched in 2014 in LDT mode, using NGS technology to detect 73 tumor-related genes, through gene expression analysis, to help doctors determine that treatment is more suitable for patients with advanced solid tumors.
    addition, guardant360 can also be used to speed up clinical trials of new drugs, help pharmaceutical companies select target patients, speed up patient grouping and research and development progress.
    According to official data, Guardant360 has been widely used in blood-based genetic analysis in more than 150 peer-reviewed publications, gained the trust of more than 7,000 oncologists, accumulated more than 150,000 clinical samples of reports, and has more than 60 biopharmaceutical partners.
    In August 2020, Guardant360 CDx was approved by the FDA for comprehensive genomic analysis of all solid tumor types, and the FDA approved it as an accompanying diagnostic tool for identifying metastasis non-small cell lung cancer patients with metastasis growth factor (EGFR) gene mutations.
    Guardant360 CDx is the first FDA-approved NGS liquid biopsy product.
    that, PGDx's elio? Plasma Resolve has also been approved for listing by the European Union CE.
    these two products were approved, to make up for the tumor gene testing market only NGS tissue biopsy products, announced that NGS liquid biopsy officially from clinical research to clinical applications.
    and china has approved the fluorescent PCR-based liquid biopsy products on the market, has not yet approved NGS-based liquid biopsy products.
    : Testing 500 tumor-related genes and empowering new drug developmentGuardant Health notes that immunotherapy and targeted therapy have been a top priority for drug companies since 2016.
    , the company launched GuardantOMNI in 2017 to provide pharmaceutical companies with comprehensive genetic analysis tools to help them accelerate clinical trials and develop targeted cancer drugs and immunotherapy.
    GuardantOMNI detects 500 tumor-related genes, which is much broader than TheGuardant 360, with an accuracy of 99.3 percent, and can detect genetic variants that doctors can't check.
    : For postoperative monitoring, patients at risk of tumor recurrence are detected earlier than traditional techniques and need to be reviewed regularly to monitor whether the tumor has returned.
    Lunar-1 is a product for cancer recurrence monitoring, focusing on lung cancer, breast cancer, colorectal cancer and ovarian cancer 4 cancer species, can detect early signs of recurrence, improve the patient's recurrence period, all aspects of performance beyond traditional technology.
    , Lunar-1 can also be used to help pharmaceutical companies develop new drugs.
    , the product has not yet entered clinical use, limited to scientific research.
    : For early cancer detection, early screening of tumors with potential market value is considered an effective means to improve the survival rate of tumor patients, due to technical limitations, the prevalence of early screening of tumors is low.
    Health is developing a blood-based cancer early screening product, Lunar-2, aimed primarily at individuals who are asymptomatic but at higher risk of cancer due to genetic factors, smoking and other factors.
    the product is in the development phase, and in Its latest annual report, Guardant Health forecasts LUNAR-2 market space of $33 billion.
    October 2019, Guardant Health launched the ECLIPSE trial to assess the potential of Lunar-2 screening for early colorectal cancer.
    in its second-quarter 2020 financial report, the company disclosed that Lunar-2 was 90 percent sensitive and 94 percent specific in early colorectal cancer testing.
    that eclipse test results are key to supporting Lunar-2's FDA approval.
    In May 2017, Guardant Health launched the Guardant 1 Million program, which aims to sequence the fluid biopsy genes of 1 million cancer patients within five years, in the hope of driving advances in cancer treatment with sequencing data and accelerating the development of the blood-testing-based cancer early screening industry.
    the plan marks the company's official focus on early screening for cancer.
    has established partnerships with leading pharmaceutical companies to accumulate data and increase revenue based on liquid biopsy technology, and Guardant Health has established partnerships with pharmaceutical companies around the world, including AstraZeneza, Pfizer and Mercadon, which are divided into two parts: joint development of accompanying diagnostic products and joint development of innovative drugs.
    2017, Guardant Health and Mercadon teamed up to help Mercadon screen potentially beneficial patients through Guardant360 CDx for clinical Phase II trials of the lung cancer-targeted drug C-MET inhibitor Tepotinib.
    2018, the company teamed up with AstraZeneta to provide accompanying diagnostic products for AstraZeneta's advanced non-small cell lung cancer drug Tagrisso.
    through extensive collaboration with pharmaceutical companies, Guardant Health not only increases revenue, but also accumulates relationships between genetic mutations and drug erring, creating a proprietary database that can be used to better guide drug use.
    the drug is successfully marketed, the company's diagnostic technology can also be sold as a binding to its accompanying diagnostic products.
    do we get a good position? Tumor liquid biopsies are a hot topic, and Guardant Health faces a number of competitors, including Grail, the star company recently acquired by Illumina for $8 billion.
    let's make a simple comparison.
    Grail is a veritable "funding king" in terms of financing, with a total of $1.69 billion, a far cry from Guardant Health, with only $550 million;
    addition to Grail, Guardant Health's competitors include Foundation Medicine, Freenome, Myriad and others.
    , Guardant Health still gives eye-catching financial data performance in the face of intense competition.
    's August 2020 financial report for the second quarter of 2020 showed that the company completed 16,499 tests in the second quarter, including 13,694 for clinical clients, up 15% year-on-year and 2,805 for pharmaceutical customers, a 47% decrease from the same period last year.
    revenue was $66.3 million in the second quarter, up 23% from a year earlier, including $51 million in oncology precision diagnostics, up 21% year-on-year, and $15.3 million in research and development services, up 29% year-on-year.
    , Guardant Health's core revenue comes from its cancer precision diagnostics business, which accounts for about 77 percent of total revenue, and the increase is due to higher average selling prices.
    , the company's test sample size for clinical customers increased, indicating that the company's products in the clinical market has been recognized gradually increased.
    significant decline in the number of test samples for pharmaceutical customers is due to fluctuations in sample size and the negative impact of outbreaks due to the progress of clinical research.
    research and development services revenue is not high, but rapid growth, the future will continue to be one of the company's core business investment, the company said in the report will continue to open up new pharmaceutical customers, to maintain existing customers.
    's oncology precision business revenue comes from Theguardant 360 and GuardantOMNI, which will continue to grow as the sales force expands and marketing activities strengthen.
    , the cancer early screening product Lunar-2 is bound to make a significant contribution to the company's revenue when it enters the market.
    , what can Guardant Health do for domestic companies? In terms of product layout, Guardant Health continues to expand from advanced tumors to prognosto surveillance and early screening.
    In the domestic cancer guidance drug competition is becoming more and more white hot, domestic enterprises also need to continue to extend the product line, open up new business direction, full monitoring and early screening are good development direction, Guardant Health's product strategy is worth reference.
    Compared with the guiding drug, the data accumulation of full monitoring and early screening, as well as the detection sensitivity, specificity requirements are higher, is undoubtedly a greater challenge to tumor liquid biopsy enterprises, enterprises also need to continuously improve their technical strength, the accumulation of more data, such as health control gene information big data.
    Health maintains a strong relationship with some of the world's leading pharmaceutical companies in terms of research and development services.
    many testing items belong to the "one hammer sale", profit plight, burning money has been genetic testing.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.